Flatiron Health is presenting multiple sessions at this year’s SCOPE Summit, advancing the conversation among stakeholders who have interest in learning how high quality, real-world data and technology embedded into point of care workflows, can improve outcomes for clinical trial participants, researchers, and the broader oncology ecosystem.
The 2024 Summit will be held February 11-14 in Orlando and aims to showcase how clinical trials and clinical research are essential for advancing medical knowledge and require the collaboration, innovation, and strategic decision-making of stakeholders from across the clinical trial ecosystem—including clinical trial participants, sites, biopharma, CROs, and technology providers.
“Flatiron’s data and technology driven clinical research solutions support study teams from trial design through study execution across all phases of clinical research - from early phase trials to post-marketing studies. Our solutions have helped sponsors and sites design and execute more efficient and inclusive clinical trials,” said Alex Deyle, General Manager, Clinical Research at Flatiron Health. “We’re looking forward to our presence at this year’s SCOPE Summit and connecting with partners, researchers and leaders, as we continue to bridge the gap between care and research.”
Highlights of Flatiron’s presence at the conference include:
Session Chair: Monday, February 12th at 10:45 AM
- Speaker: Craig Serra, Head of Clinical Research Scientific and Technical Engagement, Flatiron Health
- Track: Real World Evidence
- This session will showcase speakers from across the industry, discussing groundbreaking technologies and collaborative strategies that are redefining healthcare, with a focus on proactive wellness, precision-centered research, and innovative clinical methodologies.
Presentation Session: Monday, February 12, 2024 at 10:50 AM
Title: Applying RWD: Use Cases from Flatiron, Exact Sciences, and Johns Hopkins University
- Speakers: Josh Buddle, Director of Clinical Operations, Flatiron Health; Jonathan Helfgott, Program Coordinator, Senior Lecturer, Regulatory Science, Johns Hopkins University; Tara Marti, Associate Director, Clinical Development at Exact Sciences
- Track: Medical Device Trials
- Achieving more pragmatic approaches to clinical evidence generation requires an understanding of potential approaches and regulatory acceptance of such approaches.
- This session will review recent FDA draft guidance regarding the use of RWD/RWE in medical device studies that outline approaches and considerations for more pragmatic research. The session will also delve into case studies of companies leveraging RWE, highlighting how each case accounts for regulatory guidance and acceptance.
Presentation Session: Monday, February 12, 2024 at 4:25 PM
Title: Automating Trial Data Journeys from the Point of Care
- Speakers: Mariel Boyd, Senior Product Manager, Clinical Research, Flatiron Health; Ariel Bourla, Senior Director, Data Science and Digital Health, Johnson & Johnson R&D
- Track: Clinical Operations for Small Biopharma
- Acceleration of study data availability, without sacrificing data quality or burdening internal resources, can be the difference between success and failure for smaller, leaner biopharma sponsors.
- This talk will show how technology and technology-enabled abstraction within the EHR can enable the capture and transfer of up to 100% of study data while preserving data quality. Learn how companies of all sizes, including small and lean teams can achieve speed and efficiency, alleviate manual efforts, and create the best possible study experience.
Panel Session: Tuesday, February 13, 2024 at 9:35 AM
Title: Using RWD to Increase Patient Diversity
- Speakers: (Moderator) Marjorie Zettler, Senior Director, Clinical Science Accutar Biotechnology; (Panelists) Barry Leybovich, Senior Product Manager, Flatiron Health; Jen Banks, Director, Project Management, WEP Clinical; Dyan Bryson, Patient Engagement Strategist and Patient Advocate, Inspired Health Strategies; Susan Zelt, RWE and Clinical Scientist, Yale University; Wout Brusselaers, Founder and CEO, Deep 6 AI
- Track: Clinical Operations for Small Biopharma
- A lack of diversity and representativeness in clinical trials has been a recognized issue for decades, but despite well-intentioned efforts, there has been little meaningful progress in fixing this problem–until recently.
- Attend this expert panel to hear a discussion on how real-world data can be leveraged to improve diversity and representativeness in clinical trials.
Presentation Session: Tuesday, February 13, 2024 at 12:10 PM
Title: Trial Success Starts with Real-World Data
- Speakers: Alex Deyle, General Manager, Clinical Research, Flatiron Health; Gaelan Ritter, Head of Analytics Innovation and Digital health, Bristol-Myers Squibb
- Track: Real-World Evidence
- Today’s protocol design process relies on data from prior trials, key opinion leaders, and publications. While sometimes helpful, such data is often outdated and not reflective of current patient populations, leading to challenges with trial accrual and representativeness. Incorporating high-quality RWD into protocol development can solve this challenge—resulting in protocols that are more representative of the current natural history of disease, have more optimized eligibility criteria, and reduce protocol amendments.
- Join this presentation to learn how RWD can be used to design study protocols and hear specific, tangible examples in which this has been done successfully.
Media Contact: Nina Toor